Improper neutralization of input during web page generation ('cross-site scripting') in Active Directory Federation Services (AD FS) allows an authorized attacker to perform spoofing over a network.
Project Subscriptions
Advisories
No advisories yet.
Fixes
Solution
No solution given by the vendor.
Workaround
No workaround given by the vendor.
References
History
Tue, 14 Jul 2026 17:45:00 +0000
| Type | Values Removed | Values Added |
|---|---|---|
| Description | Improper neutralization of input during web page generation ('cross-site scripting') in Active Directory Federation Services (AD FS) allows an authorized attacker to perform spoofing over a network. | |
| Title | Active Directory Federation Server Spoofing Vulnerability | |
| First Time appeared |
Microsoft
Microsoft windows 10 1607 Microsoft windows 10 1809 Microsoft windows Server 2012 Microsoft windows Server 2012 R2 Microsoft windows Server 2016 Microsoft windows Server 2019 Microsoft windows Server 2022 Microsoft windows Server 2025 |
|
| Weaknesses | CWE-79 | |
| CPEs | cpe:2.3:o:microsoft:windows_10_1607:*:*:*:*:*:*:x86:* cpe:2.3:o:microsoft:windows_10_1809:*:*:*:*:*:*:x86:* cpe:2.3:o:microsoft:windows_server_2012:*:*:*:*:*:*:x64:* cpe:2.3:o:microsoft:windows_server_2012_R2:*:*:*:*:*:*:x64:* cpe:2.3:o:microsoft:windows_server_2016:*:*:*:*:*:*:*:* cpe:2.3:o:microsoft:windows_server_2019:*:*:*:*:*:*:*:* cpe:2.3:o:microsoft:windows_server_2022:*:*:*:*:*:*:*:* cpe:2.3:o:microsoft:windows_server_2025:*:*:*:*:*:*:*:* |
|
| Vendors & Products |
Microsoft
Microsoft windows 10 1607 Microsoft windows 10 1809 Microsoft windows Server 2012 Microsoft windows Server 2012 R2 Microsoft windows Server 2016 Microsoft windows Server 2019 Microsoft windows Server 2022 Microsoft windows Server 2025 |
|
| References |
| |
| Metrics |
cvssV3_1
|
Projects
Sign in to view the affected projects.
Status: PUBLISHED
Assigner: microsoft
Published:
Updated: 2026-07-14T18:44:58.374Z
Reserved: 2026-06-05T14:35:07.080Z
Link: CVE-2026-50684
No data.
No data.
No data.
OpenCVE Enrichment
No data.
Weaknesses